Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYC-30937-EC in active ulcerative colitis
NCT02762500Phase 2Completed
- Sponsor
- Lycera
- Start
- Jul 2016
- Primary completion
- May 2018
- Modality
- Classical Binding Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing LYC-30937-EC with Placebo (2 arms). Primary endpoint: Number of Subjects Who Achieve Clinical Remission Using Modified Mayo Score at 8 weeks. Started Jul 2016; status: completed.
02
Drugs
parimifasor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02762500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762500.